Eyeing the Extracellular Matrix in Vascular Development and Microvascular Diseases and Bridging the Divide between Vascular Mechanics and Function

• Published in: International journal of molecular sciences 2020-05, Vol.21 (10), p.3487
• Main Authors: Chaqour, Brahim, Karrasch, Charles
• Format: Article
• Language: English
• Subjects: Actomyosin; Angiogenesis; Animals; Biomechanical Phenomena; Biosynthesis; Blood vessels; Blood Vessels - embryology; Blood Vessels - growth & development; Blood Vessels - physiopathology; Cell adhesion & migration; Cell cycle; Cell growth; Collagen; Connective tissue growth factor; Cytoskeleton; Diabetes; Diabetes mellitus; Diabetic retinopathy; Extracellular matrix; Extracellular Matrix - metabolism; Eye - blood supply; Eye - embryology; Eye - pathology; Eye - physiopathology; Eye Diseases - pathology; Genetic engineering; Genetic programs; Glaucoma; growth factor; Growth factors; Heparan sulfate; Humans; Hyperoxia; Hypoxia; Integrins; Ischemia; ischemic retinopathy; Macular degeneration; Microvasculature; Microvessels - pathology; Microvessels - physiopathology; Perfusion; Proteins; Retina; Retinopathy; Review; Stiffening; Stiffness; Structure-function relationships; Vascular endothelial growth factor
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms21103487

The extracellular matrix (ECM) is critical in all aspects of vascular development and health: supporting cell anchorage, providing structure, organization and mechanical stability, and serving as a sink for growth factors and sustained survival signals. Abnormal changes in ECM protein expression, organization, and/or properties, and the ensuing changes in vascular compliance affect vasodilator responses, microvascular pressure transmission, and collateral perfusion. The changes in microvascular compliance are independent factors initiating, driving, and/or exacerbating a plethora of microvascular diseases of the eye including diabetic retinopathy (DR) and vitreoretinopathy, retinopathy of prematurity (ROP), wet age-related macular degeneration (AMD), and neovascular glaucoma. Congruently, one of the major challenges with most vascular regenerative therapies utilizing localized growth factor, endothelial progenitor, or genetically engineered cell delivery, is the regeneration of blood vessels with physiological compliance properties. Interestingly, vascular cells sense physical forces, including the stiffness of their ECM, through mechanosensitive integrins, their associated proteins and the actomyosin cytoskeleton, which generates biochemical signals that culminate in a rapid expression of matricellular proteins such as cellular communication network 1 (CCN1) and CCN2 (aka connective tissue growth factor or CTGF). Loss or gain of function of these proteins alters genetic programs of cell growth, ECM biosynthesis, and intercellular signaling, that culminate in changes in cell behavior, polarization, and barrier function. In particular, the function of the matricellular protein CCN2/CTGF is critical during retinal vessel development and regeneration wherein new blood vessels form and invest a preformed avascular neural retina following putative gradients of matrix stiffness. These observations underscore the need for further in-depth characterization of the ECM-derived cues that dictate structural and functional properties of the microvasculature, along with the development of new therapeutic strategies addressing the ECM-dependent regulation of pathophysiological stiffening of blood vessels in ischemic retinopathies.